II.i

Flash (fulminate) pulmonary edema

(Fr: OAP flash ou subit. Peut apparaitre en qq minutes). Flash PE typicall develops within minutes of exposure to the drug, sometimes after first tablet ever

Last update : 14/05/2014
 

Causative drugs

10

Heroin (intravenous)

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Pulmonary edema, cardiogenic
II.i II - Pulmonary edema - ARDS - Acute respiratory failure
II.i - Flash (fulminate) pulmonary edema
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.k IV - Airway involvement
IV.k - Bronchiectasis
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.g VI - Pulmonary vasculopathy
VI.g - Foreign body vasculopathy (Excipient lung disease)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea
IX.s IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.s - Botulism - Wound botulism
XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.s XV - Pulmonary pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.w XV - Pulmonary pathology
XV.w - Path: Pulmonary edema (see also II/IIa)
XVI.d XVI - Imaging
XVI.d - Imaging: Alveolar opacities with a batwing or butterfly distribution
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
5

Propofol

II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.f II - Pulmonary edema - ARDS - Acute respiratory failure
II.f - Hypoxemia, low saturation (may occur in isolation)
II.i II - Pulmonary edema - ARDS - Acute respiratory failure
II.i - Flash (fulminate) pulmonary edema
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.b IV - Airway involvement
IV.b - Bronchospasm and angioedema
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.e IV - Airway involvement
IV.e - Cough (acute, violent, explosive)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism
VIII.h VIII - Upper, central, large airway involvement
VIII.h - Vocal cord dysfunction, adduction, closure
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.p IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.p - Disordered breathing during sleep
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.aa X - Systemic conditions, syndromes and reactions
X.aa - Propofol infusion syndrome (PRIS)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.x XI - Miscellaneous
XI.x - Addictive risk
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XV.ae XV - Pulmonary pathology
XV.ae - Path: Lipid/fat embolism (see also VIe)
1

Rituximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.i II - Pulmonary edema - ARDS - Acute respiratory failure
II.i - Flash (fulminate) pulmonary edema
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VIII.x VIII - Upper, central, large airway involvement
VIII.x - Opportunistic large airway infection (bacterial, fungal, viral)
IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.n X - Systemic conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.av X - Systemic conditions, syndromes and reactions
X.av - Hypogammaglobulinemia-Antibody deficiency (see under XVIIw)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1